Christopher Weinert

Associate Director - Combination Product at Alnylam Pharmaceuticals - Cambridge, Massachusetts, US

Christopher Weinert's Colleagues at Alnylam Pharmaceuticals
Holly Maier

Director, Regulatory Affairs

Contact Holly Maier

Christopher Fuith

Senior Manager, Medical Device & Combination Product Development

Contact Christopher Fuith

Samuel Rigourd

Senior Director Regulatory Affairs

Contact Samuel Rigourd

Juan Lepe

Senior Director, Procurement R&D and Technology

Contact Juan Lepe

Jihong Chen

Senior Director, Biostatistics

Contact Jihong Chen

John Ko

Global Medical Director (Interim)

Contact John Ko

View All Christopher Weinert's Colleagues
Christopher Weinert's Contact Details
HQ
(617) 551-8200
Location
Greater Boston
Company
Alnylam Pharmaceuticals
Christopher Weinert's Company Details
Alnylam Pharmaceuticals logo, Alnylam Pharmaceuticals contact details

Alnylam Pharmaceuticals

Cambridge, Massachusetts, US • 2460 Employees
SaaS

ALNYLAM IS LEADING THE RNAi REVOLUTION™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, four more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,500+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-23), Science Magazine (2018-23), Fast Company (Best Workplaces for Innovators 2020-23) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email medinfo@alnylam.com or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861

Rna Therapeutics Innovative Treatments Ocular Disease Treatment
Details about Alnylam Pharmaceuticals
Frequently Asked Questions about Christopher Weinert
Christopher Weinert currently works for Alnylam Pharmaceuticals.
Christopher Weinert's role at Alnylam Pharmaceuticals is Associate Director - Combination Product.
Christopher Weinert's email address is ***@alnylam.com. To view Christopher Weinert's full email address, please signup to ConnectPlex.
Christopher Weinert works in the SaaS industry.
Christopher Weinert's colleagues at Alnylam Pharmaceuticals are Holly Maier, Chris Sullivan, Christopher Fuith, Samuel Rigourd, Juan Lepe, Jihong Chen, John Ko and others.
Christopher Weinert's phone number is (617) 551-8200
See more information about Christopher Weinert